UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000029150 |
|---|---|
| Receipt number | R000033259 |
| Scientific Title | The investigation of blood concentrations of beta-cryptoxanthin associated with long term ingestion of Ripe Kumquats "Tama-Tama". : A randomization open-label, non-eating simultaneous control comparison group study |
| Date of disclosure of the study information | 2017/09/15 |
| Last modified on | 2019/07/01 12:05:21 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The investigation of blood concentrations of beta-cryptoxanthin associated with long term ingestion of Ripe Kumquats "Tama-Tama".
: A randomization open-label, non-eating simultaneous control comparison group study
Acronym
The clinical trial for blood concentrations of beta-cryptoxanthin associated with long term ingestion of Ripe Kumquats "Tama-Tama"
Scientific Title
The investigation of blood concentrations of beta-cryptoxanthin associated with long term ingestion of Ripe Kumquats "Tama-Tama".
: A randomization open-label, non-eating simultaneous control comparison group study
Scientific Title:Acronym
The clinical trial for blood concentrations of beta-cryptoxanthin associated with long term ingestion of Ripe Kumquats "Tama-Tama"
Region
| Japan |
Condition
Condition
Healthy adults.
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate whether blood concentrations of beta-cryptoxanthin is increased or not by continuous ingestion of Ripe Kumquats "Tama-Tama" for four weeks.
Basic objectives2
Others
Basic objectives -Others
Biokinetics of functional substance.
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Serum concentrations of beta-cryptoxanthin on the first day, 8th day, 29th day and eight weeks after ingestion of Ripe Kumquats "Tama-Tama".
Key secondary outcomes
1. Natural killer cell activity
2. Interleukin-6 values
3. Body Mass Index
4. Body composition (muscle mass, fat content, body fat percentage), visceral fat area
5. Concentration of salivary amylase
6. Fatigue related scales
7. QOL scales(SF-36)
8. Adverse events.
(The secondary outcomes 1 to 5 are assessed on the first day, 8th day, 29th day and eight weeks after ingestion , and the outcomes 6 and 7 are assessed on the first day, 29th day and eight weeks after ingestion.)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Dose comparison
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
The Subjects take five Ripe Kumquats "Tama-Tama" per day for four weeks.
Interventions/Control_2
The Subjects take ten Ripe Kumquats "Tama-Tama" per day for four weeks.
Interventions/Control_3
The subjects don't take Ripe Kumquat "Tama-Tama" for four weeks.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 60 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1. Subjects who are judged as healthy by self-reported health questionnaire.
2. Subjects who have no abnormality in clinical problems by screening tests.
3. Subjects who have less than 50mcg/dL blood concentration of beta-cryptoxanthin on screening tests day.
4. Subjects who agree to participate in this study with a written informed consent after receiving sufficient explanation relating to this study.
Key exclusion criteria
1. Subjects who have respiratory, gastrointestinal, hepatic/gallbladder/pancreatic, hematologic, renal, endocrine, cardiovascular and/or mental disease, or who have history of those diseases.
2. Subjects who have a serious injury or surgical history within 12 weeks prior to this study.
3. Pre- or post-menopausal women having obvious changes in physical condition.
4. Subjects who are at risk of having allergic reaction to citrus foods including kumquat.
5. Subjects who have history of allergic reaction to foods or drugs which needs its treatment or who have possibility of the reaction.
6. Subjects who are heavy smoker (more than 21 cigarettes per day), or alcohol addicts (more than 20g per day alcohol), or alcohol or drug dependency or who have possibility of the dependency.
7. Subjects who regularly take drugs, foods for specified health uses, foods with function claims and/or supplements, etc. which would affect this study.
8. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within four weeks or blood components within two weeks prior to this study.
9. Pregnant or lactating women or women expect to be pregnant during this study.
10. Subjects who have cognitive disorder or who have possibility of the disorder.
11. Subjects who participate and take the study drug in other clinical trials within 12 weeks prior to this study.
12. Subjects who are judged as unsuitable for this study by the principal investigator or subinvestigators.
Target sample size
12
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yasuji Arimura |
Organization
University of Miyazaki
Division name
Clinical research support center, University of Miyazaki hospital
Zip code
Address
Kihara 5200, Kiyotake, Miyazaki 889-1692, Japan
TEL
0985-85-9577
yasuji_arimura@med.miyazaki-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yasuji Arimura |
Organization
University of Miyazaki
Division name
Clinical research support center, University of Miyazaki hospital
Zip code
Address
Kihara 5200, Kiyotake, Miyazaki 889-1692, Japan
TEL
0985-85-9577
Homepage URL
yasuji_arimura@med.miyazaki-u.ac.jp
Sponsor or person
Institute
University of Miyazaki
Institute
Department
Personal name
Funding Source
Organization
Miyazaki Prefecture
Organization
Division
Category of Funding Organization
Local Government
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
University of Miyazaki
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
宮崎大学医学部附属病院（宮崎県）
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 09 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 08 | Month | 14 | Day |
Date of IRB
| 2017 | Year | 09 | Month | 15 | Day |
Anticipated trial start date
| 2017 | Year | 09 | Month | 25 | Day |
Last follow-up date
| 2018 | Year | 03 | Month | 19 | Day |
Date of closure to data entry
Date trial data considered complete
| 2018 | Year | 05 | Month | 31 | Day |
Date analysis concluded
| 2019 | Year | 06 | Month | 18 | Day |
Other
Other related information
Management information
Registered date
| 2017 | Year | 09 | Month | 15 | Day |
Last modified on
| 2019 | Year | 07 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033259
